Drugs / DISC-0974
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05745883 | Apr 2023 → Oct 2025 | anemia due to chronic disorder, chronic kidney disease | Disc Medicine, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04999527 | Aug 2021 → Jun 2022 | — | Disc Medicine, Inc | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05320198 | Jun 2022 → May 2027 expected | myelodysplastic syndrome, myelofibrosis, primary myelofibrosis | Disc Medicine, Inc | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07368972 | Feb → Oct 2026 expected | anemia, inflammatory bowel disease | Disc Medicine, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 15
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | Disc Medicine, Inc | Results Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting discmedicine.com ↗ |
| 2026-06-02 | Disc Medicine, Inc | Results Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting discmedicine.com ↗
In this updated data set, treatment with DISC-0974 shows substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient types. |
| 2025-12-06 | Disc Medicine, Inc | Results Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting discmedicine.com ↗
The data demonstrated that treatment with DISC-0974 resulted in substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient types. |
| 2025-06-12 | Disc Medicine, Inc | Results Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress discmedicine.com ↗
Disc also presented longer term data from the continuation phase of its Phase 1b trial in MF anemia, showing sustained activity on key biomarkers and durable anemia response among major responders. |
| 2024-12-09 | Disc Medicine, Inc | Results Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting discmedicine.com ↗
In addition to its poster presentations, Disc presented complete results from the Phase 1b trial of DISC-0974 in anemia of myelofibrosis (MF) yesterday, December 8, in an oral presentation. |
| 2024-12-08 | Disc Medicine, Inc | Results Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting discmedicine.com ↗
The data, presented in an oral session at the 2024 American Society of Hematology (ASH) annual meeting in San Diego, CA, demonstrated that treatment with DISC-0974 results in substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient types. |
| 2024-11-12 | Disc Medicine, Inc | Results Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update discmedicine.com ↗
demonstrating that a single dose of DISC-0974 leads to consistent reductions in hepcidin and increases in transferrin saturation (TSAT), resulting in an increase in reticulocyte hemoglobin and hemoglobin |
| 2024-10-25 | Disc Medicine, Inc | Results Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week discmedicine.com ↗
The data presented at the 2024 American Society of Nephrology (ASN) Kidney Week in San Diego, CA demonstrated that a single dose of DISC-0974 results in sustained suppression of hepcidin and mobilization of iron, and increased erythropoiesis and levels of hemoglobin in NDD-CKD patients with anemia. |
| 2024-06-14 | Disc Medicine, Inc | Results Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress discmedicine.com ↗
Additionally, Disc shared updated data from a Phase 1b trial of DISC-0974 in MF anemia which demonstrated durable increases in hemoglobin and reduced transfusion burden in a majority of evaluable patients. |
| 2024-02-20 | Disc Medicine, Inc | Regulatory Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease discmedicine.com ↗
today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to DISC-0974 for the treatment of patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and anemia. |
| 2023-12-11 | Disc Medicine, Inc | Results Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting discmedicine.com ↗
Earlier today, Disc also announced initial positive data from the phase 1b study of DISC-0974 in myelofibrosis patients with anemia, demonstrating improvements in hemoglobin and reductions in transfusion burden |
| 2023-12-11 | Disc Medicine, Inc | Results Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting discmedicine.com ↗
The initial data demonstrated that treatment with DISC-0974 substantially decreased serum hepcidin, increased serum iron and resulted in improvements in hemoglobin or reduced transfusion burden across a broad range of MF patients. |
| 2022-12-13 | Disc Medicine, Inc | Results Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting discmedicine.com ↗
DISC-0974, an Anti-Hemojuvelin Antibody, Reduces Hepcidin and Mobilizes Iron in Healthy Volunteers |
| 2022-06-10 | Disc Medicine, Inc | Results Disc Medicine Presents Positive Results from Phase 1 Clinical Study of DISC-0974 in Healthy Volunteers at the 2022 EHA Annual Congress discmedicine.com ↗
The study data demonstrated robust increases in serum iron and markers of erythropoiesis, decreases in hepcidin levels, and that DISC-0974 was well-tolerated in healthy volunteers, consistent with the mechanism of action. |
| 2022-05-16 | Disc Medicine, Inc | Results Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress discmedicine.com ↗
DISC-0974 showed evidence of target engagement and iron mobilization and was generally well-tolerated. |
All press releases naming this drug 21 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DISC-0974 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05745883 ↗ |
| Action | Inhibit | “DISC-0974 is a monoclonal antibody that binds to hemojuvelin and blocks bone morphogenetic protein signaling, thereby suppressing hepcidin production.” PMID 38515275 ↗ Mar 2024 |
| Modality | Monoclonal antibody | “DISC-0974 is a monoclonal antibody that binds to hemojuvelin and blocks bone morphogenetic protein signaling, thereby suppressing hepcidin production.” PMID 38515275 ↗ Mar 2024 |
| Route | Intravenous | “administered intravenously (IV) or subcutaneously (SC)” PMID 38515275 ↗ Mar 2024 |
| Route | Subcutaneous | “administered intravenously (IV) or subcutaneously (SC)” PMID 38515275 ↗ Mar 2024 |